盐酸非索非那定片联合复方甘草酸苷治疗慢性荨麻疹的血清指标评估
|
摘要
目的探讨盐酸非索非那定片联合复方甘草酸苷对慢性荨麻疹患者血清指标的影响。方法选择2015年10月至2016年10月间进行治疗的慢性荨麻疹患者90例,按照双盲随机对照法分为接受盐酸非索非那定片联合复方甘草酸苷治疗的联合组30例、接受盐酸非索非那定片治疗的对照Ⅰ组30例、接受复方甘草酸苷治疗的对照Ⅱ组30例,均持续治疗12周。治疗前后测定两组患者血清免疫功能指标、炎症因子、趋化因子水平。结果治疗前,三组患者血清中免疫功能指标、炎症因子、趋化因子水平差异无统计学意义(P>0.05)。治疗12周后,联合组血清中Ig E水平低于对照Ⅰ组、对照Ⅱ组,C3、C4水平高于对照Ⅰ组、对照Ⅱ组;联合组血清中白细胞介素(IL)-4、IL-10、IL-17、IL-25、IL-33、单核细胞/趋化蛋白-1(MCP-1)、正常T细胞表达和分泌因子(RANTES)、嗜酸粒细胞趋化因子(Eotaxin)水平低于对照Ⅰ组、对照Ⅱ组,IL-35水平高于对照Ⅰ组、对照Ⅱ组(P<0.05)。结论盐酸非索非那定片联合复方甘草酸苷可提高慢性荨麻疹治疗效果,降低机体过敏状态并调节炎症介质。
Objective To study the effect of Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin on serum index levels in patients with chronic urticaria.Methods 90 patients with chronic urticaria who were treated in our hospital between October 2015 and October 2016 were selected and divided into the combined group(n = 30) who accepted Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin treatment,the control group Ⅰ(n = 30) who accepted Fexofenadine Hydrochloride Tablets treatment and the control group Ⅱ(n = 30) who accepted compound glycyrrhizin treatment according to the double-blind randomized controlled method,and the treatment lasted for12 weeks.Before and after treatment,serum levels of immune function indexes,inflammatory factors and chemokines of patients were determined.Results Before treatment,the differences in serum levels of immune function indexes,inflammatory factors and chemokines were not statistically significant among three groups of patients(P > 0.05).After 12 weeks of treatment,serum Ig E level of combined group was lower than that of control groupⅠ and control group Ⅱ while C3 and C4 levels were higher than those of control groupⅠ and control group Ⅱ;serum IL-4,IL-10,IL-17,IL-25,IL-33,MCP-1,RANTES and Eotaxin levels of combined group were lower than those of control group Ⅰ and control group Ⅱ while IL-35 level was higher than that of control groupⅠ and control group Ⅱ(P < 0.05).Conclusion Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin can promote the chronic urticaria treatment effect,reduce the body state of allergies and adjust the inflammatory mediators.
Objective To study the effect of Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin on serum index levels in patients with chronic urticaria.Methods 90 patients with chronic urticaria who were treated in our hospital between October 2015 and October 2016 were selected and divided into the combined group(n = 30) who accepted Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin treatment,the control group Ⅰ(n = 30) who accepted Fexofenadine Hydrochloride Tablets treatment and the control group Ⅱ(n = 30) who accepted compound glycyrrhizin treatment according to the double-blind randomized controlled method,and the treatment lasted for12 weeks.Before and after treatment,serum levels of immune function indexes,inflammatory factors and chemokines of patients were determined.Results Before treatment,the differences in serum levels of immune function indexes,inflammatory factors and chemokines were not statistically significant among three groups of patients(P > 0.05).After 12 weeks of treatment,serum Ig E level of combined group was lower than that of control groupⅠ and control group Ⅱ while C3 and C4 levels were higher than those of control groupⅠ and control group Ⅱ;serum IL-4,IL-10,IL-17,IL-25,IL-33,MCP-1,RANTES and Eotaxin levels of combined group were lower than those of control group Ⅰ and control group Ⅱ while IL-35 level was higher than that of control groupⅠ and control group Ⅱ(P < 0.05).Conclusion Fexofenadine Hydrochloride Tablets combined with compound glycyrrhizin can promote the chronic urticaria treatment effect,reduce the body state of allergies and adjust the inflammatory mediators.
引文
[1]Huang X,Li Z,Sun R.Synergistic actions of histamine-releasing factor and histamine releasing factor-reactive Ig E in chronic urticaria[J].Int Arch Allergy Immunol,2017,172(1):27-32.
[2]Díaz Palacios MA,López-Salgueiro R,Mencía Sanchez G,et al.Chronic urticaria after implantation of a mitral annuloplasty ring in a nickel-allergic patient[J].J Investig Allergol Clin Immunol,2017,27(1):74-75.
[3]刘玉林,刘春,黄连风,等.盐酸非索非那定片联合宁瘾汤治疗慢性荨麻疹44例临床观察[J].中国皮肤性病学杂志,2013,27(7):753-756.
[4]潘毅,季禾子,陆千琦.复方甘草酸苷片联合西药治疗慢性荨麻疹临床分析[J].中医,2016,48(4):189-193.
[5]中华医学会皮肤性病学分会免疫学组.中国荨麻疹诊疗指南(2014版)[J].中华皮肤科杂志,2014,47(7):514-516.
[6]韩莉,卢波,丁秋允,等.盐酸非索非那定片联合胸腺肽对慢性荨麻疹患者风团及瘙痒情况的影响[J].现代生物医学进展,2015,15(14):2738-2741.
[7]Varghese R,Rajappa M,Chandrashekar L,et al.Association among stress,hypocortisolism,systemic inflammation,and disease severity in chronic urticaria[J].Ann Allergy Asthma Immunol,2016,116(4):344-348.
[8]Pajno GB.Through the looking glass:chronic urticaria treated with anti-Ig E therapy[J].Pediatr Allergy Immunol Pulmonol,2016,29(1):56-57.
[9]罗小军,尕丽娜,郭菲,等.背俞穴拔罐对慢性荨麻疹血清总Ig E的影响及疗效观察[J].辽宁中医杂志,2013,40(3):542-545.
[10]孙晓岩,杨光忠,李庆祥,等.慢性荨麻疹患者甲状腺激素水平、免疫功能状态与病情的相关性[J].海南医学院学报,2016,22(21):258-262.
[11]种玲玲,袁永革,徐益明.慢性荨麻疹发作期与缓解期患者血清IL-4、IL-10、IL-25、IFN-γ水平变化及意义[J].山东医药,2015,55(45):81-84.
[12]Trinh HK,Pham DL,Ban GY,et al.Altered Systemic Adipokines in Patients with Chronic Urticaria[J].Int Arch Allergy Immunol,2016,171(2):102-110.
[13]孟祖东,盛晚香,王恒,等.血清白介素IL-8、IL-33和Ig E水平与慢性荨麻疹发病机制相关性研究[J].临床皮肤病杂志,2015,44(4):210-213.
[14]Moy AP,Murali M,Nazarian RM.Identification of a Th2-and Th17-skewed immune phenotype in chronic urticaria with Th22 reduction dependent on autoimmunity and thyroid disease markers[J].J Cutan Pathol,2016,43(4):372-378.
[15]郑文渊,李莹.当归四逆汤治疗慢性荨麻疹的疗效及对血清CC型趋化因子的影响[J].现代中西医结合杂志,2016,25(12):1338-1342.
[16]黄彦,梁承志,吴志洪,等.息敏颗粒合穴位敷贴对慢性荨麻疹患者血清Rantes、Mcp-1的影响[J].南京中医药大学学报,2015,31(4):320-323.
[17]Brzoza Z,Grzeszczak W,Rogala B,et al.Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria[J].Allergol Immunopathol(Madr),2014,42(4):302-306.
[18]Teran LM,Ramirez-Jimenez F,Soid-Raggi G,et al.Interleukin 16and CCL17/thymus and activation-regulated chemokine in patients with aspirin-exacerbated respiratory disease[J].Ann Allergy Asthma Immunol,2017,118(2):191-196.
[2]Díaz Palacios MA,López-Salgueiro R,Mencía Sanchez G,et al.Chronic urticaria after implantation of a mitral annuloplasty ring in a nickel-allergic patient[J].J Investig Allergol Clin Immunol,2017,27(1):74-75.
[3]刘玉林,刘春,黄连风,等.盐酸非索非那定片联合宁瘾汤治疗慢性荨麻疹44例临床观察[J].中国皮肤性病学杂志,2013,27(7):753-756.
[4]潘毅,季禾子,陆千琦.复方甘草酸苷片联合西药治疗慢性荨麻疹临床分析[J].中医,2016,48(4):189-193.
[5]中华医学会皮肤性病学分会免疫学组.中国荨麻疹诊疗指南(2014版)[J].中华皮肤科杂志,2014,47(7):514-516.
[6]韩莉,卢波,丁秋允,等.盐酸非索非那定片联合胸腺肽对慢性荨麻疹患者风团及瘙痒情况的影响[J].现代生物医学进展,2015,15(14):2738-2741.
[7]Varghese R,Rajappa M,Chandrashekar L,et al.Association among stress,hypocortisolism,systemic inflammation,and disease severity in chronic urticaria[J].Ann Allergy Asthma Immunol,2016,116(4):344-348.
[8]Pajno GB.Through the looking glass:chronic urticaria treated with anti-Ig E therapy[J].Pediatr Allergy Immunol Pulmonol,2016,29(1):56-57.
[9]罗小军,尕丽娜,郭菲,等.背俞穴拔罐对慢性荨麻疹血清总Ig E的影响及疗效观察[J].辽宁中医杂志,2013,40(3):542-545.
[10]孙晓岩,杨光忠,李庆祥,等.慢性荨麻疹患者甲状腺激素水平、免疫功能状态与病情的相关性[J].海南医学院学报,2016,22(21):258-262.
[11]种玲玲,袁永革,徐益明.慢性荨麻疹发作期与缓解期患者血清IL-4、IL-10、IL-25、IFN-γ水平变化及意义[J].山东医药,2015,55(45):81-84.
[12]Trinh HK,Pham DL,Ban GY,et al.Altered Systemic Adipokines in Patients with Chronic Urticaria[J].Int Arch Allergy Immunol,2016,171(2):102-110.
[13]孟祖东,盛晚香,王恒,等.血清白介素IL-8、IL-33和Ig E水平与慢性荨麻疹发病机制相关性研究[J].临床皮肤病杂志,2015,44(4):210-213.
[14]Moy AP,Murali M,Nazarian RM.Identification of a Th2-and Th17-skewed immune phenotype in chronic urticaria with Th22 reduction dependent on autoimmunity and thyroid disease markers[J].J Cutan Pathol,2016,43(4):372-378.
[15]郑文渊,李莹.当归四逆汤治疗慢性荨麻疹的疗效及对血清CC型趋化因子的影响[J].现代中西医结合杂志,2016,25(12):1338-1342.
[16]黄彦,梁承志,吴志洪,等.息敏颗粒合穴位敷贴对慢性荨麻疹患者血清Rantes、Mcp-1的影响[J].南京中医药大学学报,2015,31(4):320-323.
[17]Brzoza Z,Grzeszczak W,Rogala B,et al.Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria[J].Allergol Immunopathol(Madr),2014,42(4):302-306.
[18]Teran LM,Ramirez-Jimenez F,Soid-Raggi G,et al.Interleukin 16and CCL17/thymus and activation-regulated chemokine in patients with aspirin-exacerbated respiratory disease[J].Ann Allergy Asthma Immunol,2017,118(2):191-196.